Investor Relations

You are here

The Investor Relations department represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic communication. Through active, reliable and transparent investor relations work, the aim is to enable MorphoSys's investors to make a realistic assessment of the Company.


20/10/2021
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in...
11/10/2021
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy...
26/08/2021
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(...


Wed
10
'21
Nov

Third Quarter Interim Statement 2021

Thu-Tue
09-14
'21
Dec
Dec

American Society of Hematology

Atlanta, Georgia, USA
Date
Title
Add to Calendar
  1. 03/15/2021

    Year-End Results 2020

  2. 05/05/2021

    First Quarter Interim Statement 2021

  3. 05/19/2021

    Annual General Meeting 2021

  4. 07/28/2021

    Half-Year Report 2021

  5. 11/10/2021

    Third Quarter Interim Statement 2021


Annual General Meeting



Investor Contact

Dr. Julia Neugebauer

Senior Director Investor Relations

Phone: +49 89 89927 179

Email Contact
LinkedIn-Profile

Myles Clouston

Senior Director, Head of US Investor Relations

Phone: +1 857 772 0240

Email Contact